Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4941553 | 0.92 | ALDH1A1 (0.50) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL4941311 | 0.85 | HSP90AA1 (0.48) | MAPTALDH1A1LMNATSHRKMT2A | |
| SCHEMBL14116737 | 0.85 | HSP90AA1 (0.39) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL13472999 | 0.85 | HSP90AA1 (0.39) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL27690762 | 0.84 | HTR6 (0.36) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL14116738 | 0.82 | TSHR (0.52) | ALDH1A1LMNASMN1; SMN2TP53TSHR | |
| SCHEMBL4943504 | 0.80 | ALPL (0.44) | MAPTALDH1A1SMN1; SMN2TSHRNPC1 | |
| SCHEMBL4942328 | 0.80 | TSHR (0.41) | MAPTALDH1A1LMNASMN1; SMN2TP53 | |
| SCHEMBL4937213 | 0.80 | HSP90AA1 (0.41) | MAPTALDH1A1LMNASMN1; SMN2TSHR | |
| SCHEMBL27710780 | 0.78 | SMN1; SMN2 (0.34) | MAPTALDH1A1LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618285-B2 | Triazole derivatives | MERCK PATENT GMBH (DE) | 2013-12-31 | — | — | US | disclosed |
| EP-1853570-B1 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-24 | — | — | EP | disclosed |
| US-20080182857-A1 | Triazole Derivatives | MERCK PATENT GMBH (DE) | 2008-07-31 | — | — | US | disclosed |
| EP-1853570-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | Merck Patent GmbH (DE) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087077-A2 | HSP90-INHIBITING TRIAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182857-A1 | Triazole Derivatives | HSP90AB1, HSP90AA1, HSP90B1 | MAPT 2318/4885ALDH1A1 1580/4885LMNA 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.